236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 2

For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.Topics discussed include:How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)The flexibility and rapid scalability of using plants for biomanufacturing (05:06)Speeding up process development with transient expression versus transgenic plants (05:45)Regulatory perspectives and the approval process for plant-produced biologics (06:52)An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)Smart insight:Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: [email protected] Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show